DCTH - DELCATH SYSTEMS, INC.

9.68
0.310   3.202%

Share volume: 452,821
Last Updated: 03-11-2026
Medical Equipment/Surgical, Medical, And Dental Instruments And Supplies: -0.02%

PREVIOUS CLOSE
CHG
CHG%
$9.37
0.31
0.03%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
32%
Profitability 25%
Dept financing 25%
Liquidity 15%
Performance 45%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
6.14%
1 Month
6.14%
3 Months
-6.65%
6 Months
-10.70%
1 Year
-20.72%
2 Year
151.76%
Key data
Stock price
$9.68
P/E Ratio 
132.10
DAY RANGE
$9.15 - $9.70
EPS 
$0.08
52 WEEK RANGE
$8.12 - $18.23
52 WEEK CHANGE
-$19.87
MARKET CAP 
356.669 M
YIELD 
N/A
SHARES OUTSTANDING 
34.746 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-13-2025
BETA 
2.57
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$507,302
AVERAGE 30 VOLUME 
$523,076
Company detail
CEO: Gerard J. Michel
Region: US
Website: delcath.com
Employees: 60
IPO year: 2002
Issue type: Common Stock
Market: XNAS
Industry: Medical Equipment/Surgical, Medical, And Dental Instruments And Supplies
Sector: Manufacturing

Delcath Systems, Inc. focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver.

Recent news